n(4)-hydroxycytidine has been researched along with nirmatrelvir in 2 studies
| Studies (n(4)-hydroxycytidine) | Trials (n(4)-hydroxycytidine) | Recent Studies (post-2010) (n(4)-hydroxycytidine) | Studies (nirmatrelvir) | Trials (nirmatrelvir) | Recent Studies (post-2010) (nirmatrelvir) |
|---|---|---|---|---|---|
| 42 | 1 | 32 | 188 | 5 | 182 |
| Protein | Taxonomy | n(4)-hydroxycytidine (IC50) | nirmatrelvir (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Human coronavirus 229E | 0.145 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 0.0471 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caaveiro, JMM; Hamada, R; Hiramoto, T; Hirose, Y; Isogai, H; Kawanishi, E; Matsunaga, N; Mori, M; Ochi, J; Ohdo, S; Ojida, A; Onitsuka, S; Orba, Y; Sasaki, M; Sato, A; Sawa, H; Shindo, N; Takahashi, D; Toba, S; Ueda, T; Yoshida, Y | 1 |
| André, E; Chiu, W; De Jonghe, S; Jochmans, D; Leyssen, P; Maes, P; Neyts, J; Raymenants, J; Slechten, B; Vangeel, L | 1 |
2 other study(ies) available for n(4)-hydroxycytidine and nirmatrelvir
| Article | Year |
|---|---|
Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease.
Topics: Antiviral Agents; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Cysteine; Cysteine Endopeptidases; Humans; Peptide Hydrolases; Peptides; Protease Inhibitors; SARS-CoV-2 | 2022 |
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
Topics: Adenosine; Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Lactams; Leucine; Microbial Sensitivity Tests; Nitriles; Proline; RNA-Dependent RNA Polymerase; SARS-CoV-2; Vero Cells; Virus Replication | 2022 |